⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7158784 | 0.79 | — | — | |
| SCHEMBL9718360 | 0.68 | — | — | |
| SCHEMBL859281 | 0.68 | — | — | |
| SCHEMBL6841296 | 0.68 | — | — | |
| SCHEMBL7110107 | 0.65 | GRIK1 (0.31) | — | |
| SCHEMBL11593267 | 0.65 | GRIK1 (0.34) | — | |
| SCHEMBL11501282 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL27735934 | 0.62 | — | — | |
| SCHEMBL8597260 | 0.61 | ALDH1A1 (0.31) | — | |
| SCHEMBL10757691 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605264-B2 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-20 | — | — | US | claimed |
| US-7273881-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | claimed |
| EP-1708701-B1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1841750-B1 | HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8013004-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1844028-B1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1896434-B1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100113532-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-7642273-B2 | Bridged tricyclic (e.g 9,10-ethanoanthracene) derivatives of (2-carbonylamino)thiazol-5-yloxoacetamides; treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF- kappa B activity including obesity, diabetes, inflammatory and immune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7625921-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7605264-B2 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-20 | — | — | US | disclosed |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-6756360-B1 | PHOSPHONATE, PHOSPHATE AND BISAMINO PHOSPHONATE DERIVATIVES | METABASIS THERAPEUTICS, INC. | 2004-06-29 | — | — | US | disclosed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |